Compounds > ihvr-11029
Page last updated: 2024-11-13

ihvr-11029

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

IHVR-11029: inhibits endoplasmic reticulum alpha-glucosidases; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60168115
CHEMBL ID2163421
MeSH IDM000609203

Synonyms (7)

Synonym
CHEMBL2163421
MS-26075
1383152-30-4
ihvr-11029
HY-117721
CS-0067024
AKOS040748565

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In male Sprague-Dawley rats, compound 3l was well tolerated at a dose up to 200 mg/kg and displayed desirable PK profiles, with significantly improved bioavailability (F = 92 ± 4%)."( Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
Block, TM; Chang, J; Cuconati, A; Du, Y; Gill, T; Guo, JT; Qu, X; Wang, L; Xu, X; Ye, H; Yu, W; Zhao, K, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID698120Selectivity index, ratio of CC50 for BHK cells to EC50 for DENV-2 NGC infected in BHK cells2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698104Tmax in Sprague-Dawley rat at 25 mg/kg, po2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698109Acute toxicity in Sprague-Dawley rat assessed as occurrence of diarrhea at 200 mg/kg, po measured at 1 to 2 days2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698133Plasma protein binding in mouse plasma2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698114Antiviral activity against 0.01 MOI DENV infected in human Huh7.5 cells assessed as reduction in viral E2 protein level at 0.1 to 100 uM after 2 days by Western blotting2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698121Cytotoxicity against BHK cells assessed as cell viability by MTT assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698122Antiviral activity against 0.01 MOI DENV-2 NGC infected in BHK cells assessed as reduction in viral titer after 48 hrs2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698117Metabolic stability in human liver microsomes at 60 mins2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698135Plasma protein binding in human plasma2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID758253Metabolic stability in human liver microsomes assessed as compound remaining at 2 uM after 60 mins in presence of NADPH2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus.
AID698126Inhibition of human CYP3A4 using testosterone as substrate at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698125Antiviral activity against 1 MOI BVDV NADL infected in MDBK cells assessed as reduction in viral titer after 22 hrs2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698110Acute toxicity in Sprague-Dawley rat assessed as occurrence of soft feces at 50 to 100 mg/kg, po measured at 1 to 2 days2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698118Permeability across basolateral to apical side in human Caco2 cells assessed as compound recovery2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698132Inhibition of human CYP1A2 at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698102Competitive inhibition of endoplasmic reticulum-resident alpha-glucosidase in MDBK cells infected with 1 MOI BVDV assessed as decrease in viral E2 protein mobility at 0.8 to 100 uM after 24 hrs by Western blotting2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698124Cytotoxicity against MDBK cells assessed as cell viability by MTT assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID1460459Inhibition of endoplasmic reticulum alpha-glucosidase in HEK293 cells infected with DENV assessed as reduction in viral infection2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.
AID698115Metabolic stability in mouse liver microsomes at 60 mins2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698103Oral bioavailability in Sprague-Dawley rat at 25 mg/kg2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698130Inhibition of human CYP2C19 at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698137Aqueous solubility in PBS at pH 42012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID758254Metabolic stability in rat liver microsomes assessed as compound remaining at 2 uM after 60 mins in presence of NADPH2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus.
AID698131Inhibition of human CYP2C9 at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698136Aqueous solubility in PBS at pH 7.42012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698134Plasma protein binding in rat plasma2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698128Efflux ratio of permeability in human Caco2 cells2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698113Cytotoxicity against human Huh7.5 cells assessed as cell viability by MTT assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID758252Metabolic stability in mouse liver microsomes assessed as compound remaining at 2 uM after 60 mins in presence of NADPH2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus.
AID698123Selectivity index, ratio of CC50 for MDBK cells to EC50 for BVDV NADL infected in MDBK cells2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698112Acute toxicity in Sprague-Dawley rat assessed as mortality at 25 to 200 mg/kg, po after 7 days2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698108Plasma half life in Sprague-Dawley rat at 5 mg/kg, iv2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698105Cmax in Sprague-Dawley rat at 25 mg/kg, po2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698107Volume of distribution in Sprague-Dawley rat at 5 mg/kg, iv2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698116Metabolic stability in rat liver microsomes at 60 mins2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698111Acute toxicity in Sprague-Dawley rat assessed as body weight loss at 25 to 200 mg/kg, po after 7 days2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698129Inhibition of human CYP3A4 using midazolam as substrate at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698127Inhibition of human CYP2D6 at 10 uM2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698119Permeability across apical to basolateral side in human Caco2 cells assessed as compound recovery2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
AID698106Volume of distribution in Sprague-Dawley rat at 25 mg/kg, po2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-deoxynojirimycin
1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.		2.15102-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid		anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
miglustat
miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.		2.1510piperidines;
tertiary amino compound		anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
n-nonyl-1-deoxynojirimycin
N-nonyldeoxynojirimycin : A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group.		2.5120hydroxypiperidine;
tertiary amino compound		antiviral agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.2.1.45 (glucosylceramidase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Break-Bone Fever
[description not available]		02.4820
Dengue
An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.		02.4820
Ebola Hemorrhagic Fever
[description not available]		02.0810
Marburg Disease
[description not available]		02.0810
Marburg Virus Disease
An RNA virus infection of rhesus, vervet, and squirrel monkeys transmissible to man.		02.0810
Hemorrhagic Fever, Ebola
A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS.		02.0810